Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00189280 | Aldara for the Treatment of Large and/or Multiple sBCC | PHASE3 | COMPLETED | 111 | — | — | May 1, 2003 | Oct 1, 2007 | Feb 22, 2022 | 1 | France |
| Arm | Type | Description |
|---|---|---|
| imiqimod 5% cream | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Imiquimod | DRUG | cream 5%, 5 days out of seven, for 6 weeks |
Inclusion Criteria: * One or more sBCC on torso, neck or face * Total surface area \<= 40 sq cm Exclusion Criteria: * Pregnancy or women who are breastfeeding * Xeroderma pigmentosum, albinism, epidermodysplasia verruciformis, any genetic anomaly accompanied by skin tumors * Metatypical, adnexal,...